Portfolio Strategy: How To Drive Deal Value With Drug Target Analysis

For life sciences companies and investors, determining the value of a single product or an entire product portfolio is a crucial first step in asset investment, acquisition, or divestiture.

This requires a 360° analysis, looking at everything from a product’s intellectual property (IP) and U.S. Food and Drug Administration (FDA) regulatory exclusivity protection to the broader market landscape, competition and potential FDA regulatory hurdles.

Our Guide to Drug Target Analysis provides insight on:

• What is Drug Target Analysis?
• Managing patent portfolios
• Navigating complex FDA regulatory requirements
• Driving Deal Value

This tool should be an essential part of every life sciences company's drug program, enabling them to make informed decisions that drive deal value in their favor.

Download your Guide to Drug Target Analysis >